The following table shows the financial results for Merck & Co., Inc. and subsidiaries for the quarter ended June 30, 2007, compared with the corresponding period of the prior year.

Merck & Co., Inc.
Consolidated Results
(In Millions Except Earnings per Common Share)
Quarter Ended June 30
(Unaudited)

	2007	2006	% Change
Sales	$6,111.4	$5,771.7	6%
Costs, Expenses and Other			
Materials and production [(1)]	1,552.3	1,445.2	7
Marketing and administrative [(2)]	2,083.7	1,734.0	20
Research and development [(3)]	1,030.5	1,172.5	(12)
Restructuring costs [(4)]	55.8	(6.9)	*
Equity income from affiliates	(759.1)	(611.3)	24
Other (income) expense, net	(84.0)	(70.1)	20
Income Before Taxes	2,232.2	2,108.3	6
Taxes on Income	555.8	609.0	
Net Income	$1,676.4	$1,499.3	12
Average Shares Outstanding Assuming Dilution	2,189.2	2,187.7	
Earnings per Common Share Assuming Dilution	$0.77	$0.69	12

* > 100%

(1) Includes restructuring costs of $118.7 million in the second quarter of 2007 and $167.5 million in the second quarter of 2006 primarily related to accelerated depreciation and asset impairment costs associated with Merck's global restructuring program announced in November 2005.

(2) Includes the impact of reserving an additional $210 million in the second quarter of 2007 solely for future VIOXX legal defense costs.

(3) Research and development expenses in the second quarter of 2006 include acquired research expense of $296.3 million resulting from the acquisition of GlycoFi, Inc. This charge was associated with GlycoFi's technology platform to be used in the research and development process for which, at the acquisition date, technological feasibility had not been established and no alternative future use existed.

(4) Restructuring costs in 2007 and 2006 represent separation and other related costs, as well as gains on the sales of facilities in 2006, associated with the global restructuring program.

The following table shows the financial results for Merck & Co., Inc. and subsidiaries for the six months ended June 30, 2007, compared with the corresponding period of the prior year.

Merck & Co., Inc.
Consolidated Results
(In Millions Except Earnings per Common Share)
Six Months Ended June 30
(Unaudited)

	2007	2006	% Change
Sales	$11,880.7	$11,181.5	6%
Costs, Expenses and Other			
Materials and production [1]	3,078.1	2,787.9	10
Marketing and administrative [2]	3,885.7	3,449.0	13
Research and development [3]	2,060.6	2,114.5	(3)
Restructuring costs [4]	121.6	36.8	*
Equity income from affiliates	(1,411.7)	(1,114.7)	27
Other (income) expense, net [5]	(340.2)	(170.7)	99
Income Before Taxes	4,486.6	4,078.7	10
Taxes on Income	1,105.9	1,059.4	
Net Income	$3,380.7	$3,019.3	12
Average Shares Outstanding Assuming Dilution	2,183.4	2,189.2	
Earnings per Common Share Assuming Dilution	$1.55	$1.38	12

* > 100%

(1) Includes restructuring costs of $236.8 million in the first six months of 2007 and $372.5 million in the first six months of 2006 primarily related to accelerated depreciation and asset impairment costs associated with Merck's global restructuring program announced in November 2005.

(2) Includes the impact of reserving an additional $210 million in the second quarter of 2007 solely for future VIOXX legal defense costs.

(3) Research and development expenses in 2006 include acquired research expense of $296.3 million resulting from the acquisition of GlycoFi, Inc. This charge was associated with GlycoFi's technology platform to be used in the research and development process for which, at the acquisition date, technological feasibility had not been established and no alternative future use existed. Research and development expenses in 2006 also include restructuring costs of $55.4 million related to accelerated depreciation associated with the global restructuring program.

(4) Restructuring costs in 2007 and 2006 represent separation and other related costs, as well as gains on the sales of facilities in 2006, associated with the global restructuring program.

(5) The increase primarily reflects the favorable impact of gains on sales of assets and product divestitures.